InsidersTradesSigma
Follow the PROTHENA CORPORATION PUBLIC LIMITED COMPANY stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Market capitalisation: €479m. The latest transaction was reported on 29 July 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: ANNE KINGSTON. The full history is accessible without an account.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
Prothena Corporation Public Limited Company is a biopharmaceutical company focused on the discovery and development of therapies for neurodegenerative diseases. It is listed on NASDAQ under the ticker symbol PRTA.